Federated Hermes Inc. Sells 197,117 Shares of DexCom, Inc. (NASDAQ:DXCM)

Federated Hermes Inc. decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,145,706 shares of the medical device company's stock after selling 197,117 shares during the period. Federated Hermes Inc. owned about 0.56% of DexCom worth $266,261,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. KB Financial Partners LLC bought a new position in shares of DexCom in the first quarter valued at approximately $72,000. Bartlett & CO. Wealth Management LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $27,000. Valley National Advisers Inc. raised its stake in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. MV Capital Management Inc. raised its stake in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Finally, Harbour Investments Inc. raised its stake in shares of DexCom by 55.6% in the third quarter. Harbour Investments Inc. now owns 336 shares of the medical device company's stock valued at $31,000 after acquiring an additional 120 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on DXCM. Raymond James lifted their target price on shares of DexCom from $147.00 to $151.00 and gave the company a "strong-buy" rating in a research note on Tuesday, January 23rd. UBS Group lifted their target price on shares of DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a research note on Wednesday, April 10th. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an "outperform" rating and a $165.00 price objective for the company. StockNews.com upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research report on Wednesday, April 3rd. Finally, Citigroup boosted their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a research report on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and an average price target of $141.40.

Insider Activity

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the transaction, the chief financial officer now owns 71,142 shares of the company's stock, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, COO Jacob Steven Leach sold 14,639 shares of the business's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the transaction, the chief operating officer now owns 273,913 shares of the company's stock, valued at approximately $36,816,646.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now directly owns 71,142 shares of the company's stock, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock valued at $25,530,859 in the last quarter. Company insiders own 0.41% of the company's stock.

DexCom Trading Up 0.3 %

DXCM traded up $0.44 during trading on Thursday, reaching $134.30. 2,116,042 shares of the company's stock were exchanged, compared to its average volume of 2,984,076. The company's fifty day moving average price is $129.35 and its 200-day moving average price is $116.41. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The firm has a market capitalization of $51.78 billion, a PE ratio of 102.52, a P/E/G ratio of 2.35 and a beta of 1.20.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the business earned $0.34 EPS. The business's quarterly revenue was up 26.9% compared to the same quarter last year. As a group, equities analysts forecast that DexCom, Inc. will post 1.76 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.